Trial Profile
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Tilavonemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 01 Jun 2023 Primary endpoint (Change From Baseline Over Time in CDR-SB Score) has been met, according to Results published in the Brain.
- 01 Jun 2023 Results published in the Brain
- 05 Jul 2021 Status changed from active, no longer recruiting to completed.